News on research and diagnostics for metabolic disorders and metabolic diseases.
The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.
The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.
Baxter will distribute BioMérieux's Nephroclear CCL14 diagnostic in Europe and the US following regulatory approval and launch in those markets.
KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.
The proceeds from the round will allow the firm to begin selling its in vitro diagnostic blood test for patients with chronic kidney disease.
